Association of fish oil supplement use with preservation of brain volume and cognitive function - PubMed (original) (raw)
Association of fish oil supplement use with preservation of brain volume and cognitive function
Lori A Daiello et al. Alzheimers Dement. 2015 Feb.
Abstract
Objective: The aim of this study was to investigate whether the use of fish oil supplements (FOSs) is associated with concomitant reduction in cognitive decline and brain atrophy in older adults.
Methods: We conducted a retrospective cohort study to examine the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative and indicators of cognitive decline. Older adults (229 cognitively normal individuals, 397 patients with mild cognitive impairment, and 193 patients with Alzheimer's disease) were assessed with neuropsychological tests and brain magnetic resonance imaging every 6 months. Primary outcomes included (1) global cognitive status and (2) cerebral cortex gray matter and hippocampus and ventricular volumes.
Results: FOS use during follow-up was associated with significantly lower mean cognitive subscale of the Alzheimer's Disease Assessment Scale and higher Mini-Mental State Examination scores among those with normal cognition. Associations between FOS use and the outcomes were observed only in APOE ε4-negative participants. FOS use during the study was also associated with less atrophy in one or more brain regions of interest.
Keywords: Alzheimer's disease; Brain atrophy; Cognition; Docosahexaenoic acid; Omega-3.
Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Similar articles
- IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.
Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A. Kile S, et al. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):106-112. doi: 10.1136/jnnp-2015-311486. Epub 2015 Sep 29. J Neurol Neurosurg Psychiatry. 2017. PMID: 26420886 Clinical Trial. - Predicting the apolipoprotein E ε4 allele carrier status based on gray matter volumes and cognitive function.
Kim HG, Tian Y, Jung SM, Park S, Rhee HY, Ryu CW, Jahng GH. Kim HG, et al. Brain Behav. 2024 Jan;14(1):e3381. doi: 10.1002/brb3.3381. Brain Behav. 2024. PMID: 38376028 Free PMC article. - Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E, Zetterberg H, Skillbäck T, Törnqvist U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM, Mattsson N, Blennow K; Alzheimer’s Disease Neuroimaging Initiative. Portelius E, et al. Brain. 2015 Nov;138(Pt 11):3373-85. doi: 10.1093/brain/awv267. Epub 2015 Sep 15. Brain. 2015. PMID: 26373605 Free PMC article. - Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.
Bilello M, Doshi J, Nabavizadeh SA, Toledo JB, Erus G, Xie SX, Trojanowski JQ, Han X, Davatzikos C. Bilello M, et al. J Alzheimers Dis. 2015;48(4):987-94. doi: 10.3233/JAD-150400. J Alzheimers Dis. 2015. PMID: 26402108 Free PMC article. - The effects of synthetic glucocorticoid treatment for inflammatory disease on brain structure, function, and dementia outcomes: A systematic review.
Shorey CL, Mulla RT, Mielke JG. Shorey CL, et al. Brain Res. 2023 Jan 1;1798:148157. doi: 10.1016/j.brainres.2022.148157. Epub 2022 Nov 8. Brain Res. 2023. PMID: 36368460
Cited by
- Precision Medicine in Lifestyle Medicine: The Way of the Future?
Gray ID, Kross AR, Renfrew ME, Wood P. Gray ID, et al. Am J Lifestyle Med. 2019 Mar 20;14(2):169-186. doi: 10.1177/1559827619834527. eCollection 2020 Mar-Apr. Am J Lifestyle Med. 2019. PMID: 32231483 Free PMC article. Review. - Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease.
Devassy JG, Leng S, Gabbs M, Monirujjaman M, Aukema HM. Devassy JG, et al. Adv Nutr. 2016 Sep 15;7(5):905-16. doi: 10.3945/an.116.012187. Print 2016 Sep. Adv Nutr. 2016. PMID: 27633106 Free PMC article. Review. - Impact of multidomain preventive strategies on functional brain connectivity in older adults with cognitive complaint: Subset from the Montpellier center of the ancillary MAPT-MRI study.
Perus L, Mangin JF, Deverdun J, Gutierrez LA, Gourieux E, Fischer C, Van Dokkum LEH, Manesco C, Busto G, Guyonnet S, Vellas B, Gabelle A, Le Bars E; MAPT/DSA group. Perus L, et al. Front Aging Neurosci. 2023 Jan 10;14:971220. doi: 10.3389/fnagi.2022.971220. eCollection 2022. Front Aging Neurosci. 2023. PMID: 36705622 Free PMC article. - Use of Active Salmon-Lecithin Nanoliposomes to Increase Polyunsaturated Fatty Acid Bioavailability in Cortical Neurons and Mice.
Passeri E, Elkhoury K, Jiménez Garavito MC, Desor F, Huguet M, Soligot-Hognon C, Linder M, Malaplate C, Yen FT, Arab-Tehrany E. Passeri E, et al. Int J Mol Sci. 2021 Nov 1;22(21):11859. doi: 10.3390/ijms222111859. Int J Mol Sci. 2021. PMID: 34769291 Free PMC article. - The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review.
Kueper JK, Speechley M, Montero-Odasso M. Kueper JK, et al. J Alzheimers Dis. 2018;63(2):423-444. doi: 10.3233/JAD-170991. J Alzheimers Dis. 2018. PMID: 29660938 Free PMC article. Review.
References
- van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr. 2007;85:1142–7. - PubMed
- Barberger-Gateau P, Jutand MA, Letenneur L, Larrieu S, Tavernier B, Berr C. Correlates of regular fish consumption in French elderly community dwellers: data from the Three-City study. Eur J Clin Nutr. 2005;59:817–25. - PubMed
- Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology. 2005;65:1409–14. - PubMed
- Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol. 2006;63:1545–50. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K01 AG030514/AG/NIA NIH HHS/United States
- R01 NS036524/NS/NINDS NIH HHS/United States
- R01 HL064342/HL/NHLBI NIH HHS/United States
- K08 HS017735/HS/AHRQ HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- R01 CA155381/CA/NCI NIH HHS/United States
- T32 HL076134/HL/NHLBI NIH HHS/United States
- R01 HL084178/HL/NHLBI NIH HHS/United States
- R01 NR011295/NR/NINR NIH HHS/United States
- P30 AG028740/AG/NIA NIH HHS/United States
- U01 CA1503878/CA/NCI NIH HHS/United States
- R01DA020725/DA/NIDA NIH HHS/United States
- R01 HL089311/HL/NHLBI NIH HHS/United States
- R01 DA020725/DA/NIDA NIH HHS/United States
- R01 MH074368/MH/NIMH NIH HHS/United States
- 5T32HL076134/HL/NHLBI NIH HHS/United States
- R01 CA159954/CA/NCI NIH HHS/United States
- R01 HL109116/HL/NHLBI NIH HHS/United States
- R34DA031057-02/DA/NIDA NIH HHS/United States
- R00AA020235/AA/NIAAA NIH HHS/United States
- R01 DA021729/DA/NIDA NIH HHS/United States
- R01 DK099334/DK/NIDDK NIH HHS/United States
- U01 CA150387/CA/NCI NIH HHS/United States
- R01DA021729/DA/NIDA NIH HHS/United States
- P01AA019072/AA/NIAAA NIH HHS/United States
- R01 AT006948/AT/NCCIH NIH HHS/United States
- R18 DK075371/DK/NIDDK NIH HHS/United States
- R34 DA031057/DA/NIDA NIH HHS/United States
- R56 DK075119/DK/NIDDK NIH HHS/United States
- R01AT006948/AT/NCCIH NIH HHS/United States
- R00 AA020235/AA/NIAAA NIH HHS/United States
- R03 CA153942/CA/NCI NIH HHS/United States
- R01NS080655/NS/NINDS NIH HHS/United States
- R01 NS080655/NS/NINDS NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- R01HL109116/HL/NHLBI NIH HHS/United States
- P01 AA019072/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous